Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients

被引:48
作者
Farina, C
Vargas, V
Heydari, N
Kümpfel, T
Meinl, E
Hohlfeld, R
机构
[1] Max Planck Inst Neurobiol, Dept Neuroimmunol, D-82152 Martinsried, Germany
[2] Univ Munich, Inst Clin Neuroimmunol, D-81366 Munich, Germany
关键词
multiple sclerosis; auto immunity; TH2-lymphocytes;
D O I
10.1016/S0165-5728(01)00490-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We analysed the humoral immune response to glatiramer acetate (GA, Copaxone) in 20 multiple sclerosis patients treated with GA, 20 patients not treated with GA and 20 normal control subjects. Using an ELISA for detection of total GA-reactive immunoglobulins (all isotypes), all treated patients but also 3/20 untreated and 8/20 healthy subjects scored positive at 1:20 plasma dilutions. At higher dilutions, 5/20 treated patients and two healthy donors had relatively high levels of anti-GA antibodies. Isotype and IgG subclass analysis revealed that the two antibody-positive normal subjects had IgM and small titers of IgG1 or IgG2 antibodies. In contrast, 18 of 20 GA-treated patients, had low but significant titers of GA-reactive IgG4 antibodies. This finding is consistent with the previously described GA-mediated induction of T-helper 2 (TH2)-like regulatory T cells. (C) 2002 Elsevier Science B.V All tights reserved.
引用
收藏
页码:188 / 192
页数:5
相关论文
共 50 条
  • [42] Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients
    Rio, Jordi
    Rovira, Alex
    Tintore, Mar
    Sastre-Garriga, Jaurne
    Castillo, Joaquin
    Auger, Cristina
    Nos, Carlos
    Comabella, Manuel
    Tur, Carmen
    Vidal, Angela
    Montalban, Xavier
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (12) : 1602 - 1608
  • [43] Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate
    Chiarini, M.
    Sottini, A.
    Ghidini, C.
    Zanotti, C.
    Serana, F.
    Rottoli, M.
    Zaffaroni, M.
    Bergamaschi, R.
    Cordioli, C.
    Capra, R.
    Imberti, L.
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (02) : 218 - 227
  • [44] Normocomplementemic urticarial vasculitis in a patient with multiple sclerosis on glatiramer acetate
    Marsters, Candace
    Nathoo, Nabeela
    Amatto, Lindsay
    Wong, Russell
    Mahmood, Muhammad N.
    McCombe, Jennifer A.
    JOURNAL OF NEUROIMMUNOLOGY, 2023, 380
  • [45] Successful Rapid Desensitization to Glatiramer Acetate in a Patient With Multiple Sclerosis
    Syrigou, E.
    Psarros, P.
    Grapsa, D.
    Syrigos, K.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2015, 25 (03) : 214 - 215
  • [46] Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
    Izquierdo, Guillermo
    Garcia-Agua Soler, Nuria
    Rus, Macarena
    Jose Garcia-Ruiz, Antonio
    BRAIN AND BEHAVIOR, 2015, 5 (06): : 1 - 9
  • [47] Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
    Santa Rita Pereira, Valeria Coelho
    Malfetano, Fabiola Rachid
    Meira, Isabella D'Andrea
    de Souza, Leticia Fezer
    Liem, Assuncion Martinez
    Maiolino, Angelo
    Alves Leon, Soniza Vieira
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2012, 70 (10) : 774 - 779
  • [48] Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis
    Tjalf Ziemssen
    Oliver Neuhaus
    Reinhard Hohlfeld
    Drug Safety, 2001, 24 : 979 - 990
  • [49] Long-term effects of glatiramer acetate in multiple sclerosis
    Brochet, B.
    REVUE NEUROLOGIQUE, 2008, 164 (11) : 917 - 926
  • [50] A longitudinal observational study of a cohort of patients with relapsingremitting multiple sclerosis treated with glatiramer acetate
    Debouverie, M.
    Moreau, T.
    Lebrun, C.
    Heinzlef, O.
    Brudon, F.
    Msihid, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (11) : 1266 - 1274